Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JAM-A and sialic acid (None)
- Target
- None
- Molecular classification
- Receptor, Adhesion molecule, Immunoglobulin superfamily, Glycan, carbohydrate moiety, terminal sugar on glycoproteins/glycolipids
01
Overview
This entry should be split into two specific targets for optimal structured curation: one for “Junctional adhesion molecule A (JAM-A)” and one for “cell-surface sialic acid.” The current form is not a singular canonical target and is flagged as such.
- Other names
- Junctional adhesion molecule AJAM1F11 receptorF11RN-acetylneuraminic acid (Neu5Ac)sialoglycansialylated glycan
02
Mechanism of action
Antibodies or small molecules may block homophilic/heterophilic adhesion, inhibit downstream signaling (e.g., Rap1 activation), or disrupt tight junctions to alter cell migration/permeability. Viral attachment inhibitors block virus binding to sialic acids; sialyltransferase inhibitors alter glycosylation of surface proteins to reduce cell adhesion, spreading, or immune evasion.
03
Biological functions
Cell adhesion and tight junction formationIntracellular signalingCell migration and polarityModulation of paracellular permeabilityImmune cell transmigrationMediates cell–cell and pathogen–cell interactionsModulates immune recognition and maskingContributes to metastatic potential in cancer cells
04
Disease associations
CancerInflammationCardiovascular diseaseInfectionimmune evasion
05
Safety considerations
Potential effects on normal tissue tight junctions, barrier function, and immune cell trafficking limit therapeutic windowInhibiting sialylation may affect normal tissue protection from immune recognition and disrupt many physiological glycan-dependent processes
06
Interacting drugs
No approved drugs specifically target JAM-A, but it is a subject of anti-cancer and anti-inflammatory therapeutic development
2 more in the full profile.
07
Biomarkers
Circulating or tissue JAM-A as a biomarker for cell adhesion, metastasis, cardiovascular disease, and inflammationCell-surface sialylation level as a marker of malignancy, metastatic potentialin some infections
Beyond the preview
Go deeper on JAM-A and sialic acid (None).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAM-A and sialic acid (None).